Their primary contraceptive drug candidate is called Twirla, or AG200-15, and is administered through a contraceptive skin path. Twirla contains a combination of hormonal contraceptives such as ethinyl estradiol, and levonorgestrel, and delivers them through a skin patch over the course of a seven day period. The skin patch is administered for 3 straight weeks followed by a one week break without the skin patch.
On May 5, 2010 Agile Therapeutics completed their series A funding round with $1 million in funding from undisclosed investors.
On June 14, 2010 Agile Therapeutics completed their series B funding round with $45 million in funding from Investor Growth Capital Limited (lead investor), Care Capital (lead investor), ProQuest Investments, Novitas Capital, and Kaiser Permanente Ventures.
On July 19, 2012 Agile Therapeutics completed their series C funding round with $40 million in funding from Aisling Capital (lead investor), Care Capital, Investor Growth Capital, ProQuest Investments, Kaiser Permanente Ventures, and Novitas Capital.
On March 4, 2019 Agile Therapeutics announced a definitive stock purchase agreement with Perceptive Advisors that resulted in $7.8 million of gross proceeds for Agile Therapeutics. Perceptive Advisors were given approximately 8.4 million privately placed shares of common stock in Agile Therapeutics at $0.93 per share.
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.